Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension

Comparison with Cardiopulmonary Exercise Testing

SHOICHI MIYAMOTO, NORITOSHI NAGAYA, TORU SATOH, SHINGO KYOTANI, FUMIO SAKAMAKI, MASATOSHI FUJITA, NORIFUMI NAKANISHI, and KUNIO MIYATAKE

Division of Cardiology, Department of Medicine, National Cardiovascular Center, Osaka; and College of Medical Technology, Kyoto University, Kyoto, Japan

The six-minute walk test is a submaximal exercise test that can be performed even by a patient with heart failure not tolerating maximal exercise testing. To elucidate the clinical significance and prognostic value of the six-minute walk test in patients with primary pulmonary hypertension (PPH), we sought (1) to assess the relation between distance walked during the six-minute walk test and exercise capacity determined by maximal cardiopulmonary exercise testing, and (2) to investigate the prognostic value of the six-minute walk test in comparison with other noninvasive parameters. The six-minute walk test was performed in 43 patients with PPH, together with echocardiography, right heart catheterization, and measurement of plasma epinephrine and norepinephrine. Symptom-limited cardiopulmonary exercise testing was performed in a subsample of patients (n = 27). Distance walked in 6 min was significantly shorter in patients with PPH than in age- and sex-matched healthy subjects (297 ± 188 versus 655 ± 91 m, p < 0.001). The distance significantly decreased in proportion to the severity of New York Heart Association functional class. The distance walked correlated modestly with baseline cardiac output (r = 0.48, p < 0.05) and total pulmonary resistance (r = −0.49, p < 0.05), but not significantly with mean pulmonary arterial pressure. In contrast, the distance walked correlated strongly with peak \( \dot{V}O_2 \) (r = 0.70, p < 0.001), oxygen pulse (r = 0.57, p < 0.01), and \( V\varepsilon-VCO_2 \) slope (r = −0.66, p < 0.001) determined by cardiopulmonary exercise testing. During a mean follow-up period of 21 ± 16 mo, 12 patients died of cardiopulmonary causes. Among noninvasive parameters including clinical, echocardiographic, and neurohumoral parameters, only the distance walked in 6 min was independently related to mortality in PPH by multivariate analysis. Patients walking < 332 m had a significantly lower survival rate than those walking farther, assessed by Kaplan-Meier survival curves (log-rank test, p < 0.01). These results suggest that the six-minute walk test, a submaximal exercise test, reflects exercise capacity determined by maximal cardiopulmonary exercise testing in patients with PPH, and it is the distance walked in 6 min that has a strong, independent association with mortality.


Primary pulmonary hypertension (PPH) is a rare, but life-threatening disease characterized by progressive pulmonary hypertension (1). Most patients with PPH have severe exertional limitation owing to cardiopulmonary factors from an early phase of this disease, which ultimately leads to right ventricular (RV) failure and death. Indeed, D’Alonzo and coworkers have demonstrated a decrease in peak exercise oxygen consumption (peak \( \dot{V}O_2 \)) and an increase in the regression slope relating minute ventilation to carbon dioxide output (\( V\varepsilon-VCO_2 \) slope) in patients with PPH, using cardiopulmonary exercise testing (2). Rhodes and coworkers have shown that the ability of cardiopulmonary exercise testing to identify PPH patients at high risk for cardiac catheterization is superior to that of other noninvasive variables (3). Interestingly, peak \( \dot{V}O_2 \) and \( V\varepsilon-VCO_2 \) slope obtained from cardiopulmonary exercise testing have been shown to be related to mortality in patients with chronic heart failure (4, 5). These results raise the possibility that exercise testing can be used as a prognostic indicator in patients with PPH. However, maximal stress testing may be difficult in some patients with severe PPH (3).
The six-minute walk test is a submaximal exercise test that can be performed by a patient not tolerating maximal exercise tests (6). The test is very simple, requires inexpensive equipment, and is reproducible. In addition, it is considered safe because patients are self-limited during exercise. Recently, the distance walked in 6 min has been shown to correlate significantly with peak $\dot{V}O_2$ and $V_{E \cdot VCO_2}$ slope in patients with advanced heart failure, and thereby serves as a prognostic indicator in this disease (7, 8). In patients with PPH, the six-minute walk test has been used as a relative parameter to assess changes in functional capacity during vasodilator therapy (9, 10). However, few data exist regarding relative parameter to assess changes in functional capacity during patients with PPH, the six-minute walk test has been used as a thereby serves as a prognostic indicator in this disease (7, 8). In patients with PPH (9, 10), however, few data exist regarding clinical significance and prognostic value of the six-minute walk test in patients with PPH.

In the present study, we sought (1) to assess the relation between the distance walked during the six-minute walk test and exercise capacity determined by cardiopulmonary exercise testing in patients with PPH and (2) to investigate the prognostic value of the six-minute walk test in comparison with clinical parameters, echocardiographic findings, and plasma catecholamine levels, which had been reported to be related to mortality in patients with PPH (3, 11, 12).

### METHODS

#### Study Subjects

This study included 43 patients with PPH (13 men and 30 women; mean age, 37 yr; range, 14 to 67 yr) who were referred to our institute between December 1994 and January 1999. PPH was defined as pulmonary hypertension unexplained by any secondary cause, based on the criteria of the National Institutes of Health registry on PPH (1). Six patients were classified as New York Heart Association (NYHA) functional class II, 29 patients as class III, and eight patients as class IV. Thirty-eight patients (88%) received prostacyclin therapy: intravenous prostacyclin ($n = 13$) (9, 10, 13) or an oral prostacyclin analogue ($n = 25$) (14, 15). The remaining five patients did not receive prostacyclin therapy because four patients could not tolerate it due to hypotension resulting from uncompensated right heart failure and one patient developed hypoxia during prostacyclin therapy. All subjects gave informed consent.

#### Hemodynamic Studies

Diagnostic right heart catheterization was performed in all patients while they were in a stable condition during hospitalization. Baseline hemodynamic variables including mean pulmonary arterial pressure, mean right atrial pressure, pulmonary capillary wedge pressure, and mean systemic arterial pressure were measured in all patients. Cardiac output was measured by Fick’s method (16). Total pulmonary resistance was calculated by dividing mean pulmonary arterial pressure by cardiac output.

#### Six-minute Walk Test

The six-minute walk test was performed in all patients with PPH and 16 age- and sex-matched healthy volunteers according to a standardized protocol (6, 17). They walked along an enclosed, level, measured corridor. Technicians escorted and encouraged subjects with the standardized statements, “You are doing well” or “Keep up the good work,” but were asked not to use other phrases. Subjects were instructed to walk at their own pace but to cover as much ground as possible in 6 min. They tolerated the six-minute walk test without any adverse effects. Patients with PPH were divided into two groups according to the median value of the distance walked in 6 min: long distance group ($> 332$ m, $n = 21$) and short distance group ($< 332$ m, $n = 22$).

#### Cardiopulmonary Exercise Testing

Symptom-limited cardiopulmonary exercise testing was performed in 27 patients with PPH and 16 age- and sex-matched healthy volunteers. The remaining 16 patients with PPH were excluded from the protocol because they could not tolerate the maximal exercise test. Patients first pedaled at 55 rpm without any added load for 1 min. The work rate was then increased by 15 watt/min up until their symptom-limited maximum. Heart rate was monitored with standard electrocardio-

### TABLE 1

<table>
<thead>
<tr>
<th>Variables</th>
<th>Short Distance Group¹ ($n = 22$)</th>
<th>Long Distance Group² ($n = 21$)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, yr</td>
<td>$39 \pm 15$</td>
<td>$35 \pm 13$</td>
<td>NS</td>
</tr>
<tr>
<td>Sex, male/female</td>
<td>$6/16$</td>
<td>$7/14$</td>
<td>NS</td>
</tr>
<tr>
<td>Body surface area, m²</td>
<td>$1.5 \pm 0.2$</td>
<td>$1.6 \pm 0.2$</td>
<td>NS</td>
</tr>
<tr>
<td>Hemodynamic variables</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate, beats/min</td>
<td>$81 \pm 15$</td>
<td>$75 \pm 11$</td>
<td>NS</td>
</tr>
<tr>
<td>$Pp_{sa}$, mm Hg</td>
<td>$82 \pm 8$</td>
<td>$85 \pm 10$</td>
<td>NS</td>
</tr>
<tr>
<td>$Pp_{pa}$, mm Hg</td>
<td>$61 \pm 11$</td>
<td>$54 \pm 12$</td>
<td>NS</td>
</tr>
<tr>
<td>$Q$, L/min</td>
<td>$2.6 \pm 0.7$</td>
<td>$3.9 \pm 3.3$</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>TPR, Wood units</td>
<td>$24 \pm 6$</td>
<td>$16 \pm 7$</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>$Ppa$, mm Hg</td>
<td>$9 \pm 4$</td>
<td>$6 \pm 4$</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>$Ppcw$, mm Hg</td>
<td>$8 \pm 4$</td>
<td>$7 \pm 3$</td>
<td>NS</td>
</tr>
<tr>
<td>Blood gas variables</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$Sao_2$, %</td>
<td>$93 \pm 4$</td>
<td>$95 \pm 3$</td>
<td>NS</td>
</tr>
<tr>
<td>$Sao_2$, %</td>
<td>$55 \pm 8$</td>
<td>$66 \pm 6$</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Neurohumoral factors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma NE, pg/ml</td>
<td>$534 \pm 500$</td>
<td>$315 \pm 196$</td>
<td>NS</td>
</tr>
<tr>
<td>Plasma EPI, pg/ml</td>
<td>$57 \pm 63$</td>
<td>$39 \pm 27$</td>
<td>NS</td>
</tr>
<tr>
<td>Medication use, n</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intravenous prostacyclin</td>
<td>$8$</td>
<td>$5$</td>
<td>NS</td>
</tr>
<tr>
<td>Oral prostacyclin analogue</td>
<td>$11$</td>
<td>$14$</td>
<td>NS</td>
</tr>
<tr>
<td>Anticoagulant agents</td>
<td>$16$</td>
<td>$15$</td>
<td>NS</td>
</tr>
</tbody>
</table>

Definition of abbreviations: EPI = epinephrine; NE = norepinephrine; NS = not significant; $Ppa$ = mean pulmonary arterial pressure; $Ppcw$ = pulmonary capillary wedge pressure; $Pra$ = mean right atrial pressure; $Psa$ = mean systemic arterial pressure; $Q$ = cardiac output; $Sao_2$ = arterial oxygen saturation; $Sao_2$ = mixed venous oxygen saturation; TPR = total pulmonary resistance.

¹ Values are expressed as mean ± SD unless otherwise indicated.

² Short distance group = patients walking $< 332$ m in 6 min.

³ Long distance group = patients walking $\geq 332$ m in 6 min.
graphic leads, and blood pressure was measured at the brachial artery with a sphygmomanometer. Breath-by-breath gas analysis was performed using an AE280 (Minato Medical Science, Osaka, Japan) connected to a personal computer running analyzing software (18).

The anaerobic threshold (AT) was chosen as the \( V_{O_2} \) at which the \( V_{E}/V_{CO_2} \) increased while the \( V_{E}/V_{CO_2} \) decreased or remained constant. Peak \( V_{O_2} \) was defined as the value of averaged data during the final 15 s of exercise. The oxygen pulse was calculated by dividing \( V_{O_2} \) by heart rate, an index of stroke volume during exercise. The \( V_{E} \)-\( V_{CO_2} \) slope was determined as the linear regression slope of \( V_{E} \) and \( V_{CO_2} \) from the start of exercise until the RC point (the time up until which ventilation is stimulated by \( CO_2 \) output and end-tidal \( CO_2 \) tension begins to decrease) (19).

**Blood Sampling and Assay for Neurohormones**

Blood samples were drawn from a peripheral vein at diagnostic catheterization while the patient was in a stable hemodynamic state and not receiving vasodilator drugs. Blood was immediately transferred into a chilled glass tube containing disodium ethylenediaminetetraacetic acid (EDTA) (1 mg/ml), and plasma epinephrine and norepinephrine were measured as reported previously (20).

**Echocardiographic Assessment**

Echocardiography was performed with a Toshiba SSH-120A (Tokyo, Japan). Parasternal short-axis views were obtained at the papillary muscle level of the left ventricle (LV) using a 3.5-M Hz sector transducer. The longest (L) and the shortest (S) diameters of the LV cavity were measured at the point of maximal deformation in early diastole. The LV deformity index was calculated as \( L/S \) (21). Pericardial effusions were also evaluated in the parasternal short-axis views in early diastole and graded as absent, small (separation less than 1 cm), or large (separation more than 1 cm).

**Survival Estimates**

Survival was estimated from the date of initial diagnosis to February 28, 1999, or the death of the patient. No patient received lung or heart-lung transplantation during the follow-up period. No patient died of noncardiopulmonary causes. The follow-up rate was 100%.

**Statistical Analysis**

All data were expressed as mean values ± SD. Comparisons between two groups were made by Fisher exact test or unpaired Student’s t test. Comparisons of parameters among the four groups were made using one-way analysis of variance, followed by Scheffe’s multiple comparison test. Correlation coefficients between distance walked in 6 min and other variables were determined by linear regression analysis. To determine whether the six-minute walk test has independent prognostic significance, the following eight variables were entered into a multivariate Cox proportional hazards regression analysis: age, sex, plasma norepinephrine, heart rate, arterial oxygen saturation, presence of pericardial effusion, LV deformity index, and the distance walked in 6 min. Survival curves according to the median value (332 m) of the distance walked in 6 min were derived using the Kaplan-Meier method and were compared using log-rank test. A p value < 0.05 was considered statistically significant.

**RESULTS**

**Patient Characteristics**

Demographic, hemodynamic, and neurohumoral data of the patients grouped according to the median value (332 m) of the distance walked in 6 min are summarized in Table 1. There were no significant differences in demographics between the long distance group and the short distance group. Cardiac output and mixed venous oxygen saturation were significantly lower in the short distance group than in the long distance group. Total pulmonary resistance and mean right atrial pressure were significantly higher in the short distance group than the long distance group.
in the long distance group. Neither plasma epinephrine nor norepinephrine level significantly differed between the two groups. There was no significant difference in medication use between the two groups.

**Relations between Six-minute Walk Test and Clinical, Hemodynamic, and Neurohumoral Parameters**

Distance walked in 6 min was significantly lower in patients with PPH than in healthy subjects (297 ± 188 versus 655 ± 91 m, p < 0.001). The distance significantly decreased in proportion to the severity of NYHA functional class (Figure 1). The distance walked in 6 min did not significantly correlate with mean pulmonary arterial pressure at baseline (Figure 2). In contrast, the distance walked was modestly, but significantly, correlated with cardiac output and total pulmonary resistance at baseline values. The distance walked in 6 min was not significantly correlated with plasma epinephrine or norepinephrine at baseline values.

**Relations between the Six-minute Walk Test and Maximal Cardiopulmonary Exercise Testing**

AT, peak $V_O_2$, and oxygen pulse were markedly lower in patients with PPH than in healthy subjects (AT, 8.0 ± 2.1 versus 17.9 ± 4.5 ml/kg/min; peak $V_O_2$, 13.4 ± 4.3 versus 36.4 ± 7.8 ml/kg/min; oxygen pulse, 0.09 ± 0.03 versus 0.21 ± 0.06 ml/kg, p < 0.001, respectively). The $VE\cdot V_CO_2$ slope was significantly higher in patients with PPH than in healthy subjects (42.5 ± 8.6 versus 24.5 ± 2.4, p < 0.001). Distance walked in 6 min showed strong positive correlations with peak $V_O_2$ and oxygen pulse determined by maximal cardiopulmonary exercise testing (Figure 3). The distance walked showed a strong negative correlation with $VE\cdot V_CO_2$ slope. The distance walked was modestly, but significantly, correlated with AT.

**Six-minute Walk Test and Mortality in PPH**

During a mean follow-up period of 21 ± 16 mo, 12 patients died of cardiopulmonary causes: seven patients died of progressive RV failure and five patients died suddenly. Among noninvasive variables, i.e., distance walked in 6 min, age, sex, plasma norepinephrine, heart rate, arterial oxygen saturation, presence of pericardial effusion, and LV deformity index, only the distance walked was independently related to mortality in PPH by multivariate Cox proportional hazards analysis (Table 2).

The Kaplan-Meier survival curves grouped according to the median value of the distance walked in 6 min demonstrated that patients walking < 332 m had a significantly lower survival rate than those walking farther (log-rank test, p < 0.01, Figure 4).

**DISCUSSION**

In this study, we demonstrated that distance walked during the six-minute walk test significantly decreased in proportion to the severity of NYHA functional class in patients with PPH, and that distance walked in 6 min was significantly correlated with baseline cardiac output, total pulmonary resistance, and mean right atrial pressure. We also demonstrated that the distance walked in 6 min was strongly correlated with peak $V_O_2$,
useful in predicting peak $O_2$ in patients with severe heart failure (25). Unlike our study, however, Cahalin et al. failed to define a close association of the six-minute walk test with the results of maximal exercise testing in all patients. Unlike our study, Guyatt and co-workers speculate that a decreased cardiac reserve during exercise in this disease (2, 3). Unfortunately, however, cardiopulmonary exercise testing could not be performed in the most severe forms of PPH in this study, consistent with an earlier study (3). In contrast, the six-minute walk test, a submaximal exercise test, could be performed in all patients with PPH. Thus, this submaximal test may be applicable for evaluation of exercise capacity in patients with PPH. In fact, the six-minute walk test has been used as a relative parameter to assess changes in functional capacity during vasodilator therapy (9, 10). However, little information is available regarding clinical significance of the six-minute walk test in patients with PPH.

In the present study, we first demonstrated that distance walked in 6 min decreased in proportion to the decrease in peak $V_{O_2}$ and oxygen pulse determined by maximal cardiopulmonary exercise testing. On the other hand, the distance walked correlated modestly with baseline hemodynamic parameters. Considering that oxygen pulse is representative of changes in stroke volume during exercise (24), these results suggest that the distance walked during the six-minute walk test may reflect insufficient oxygen delivery to the body during exercise at least due to an inadequate increase in stroke volume during exercise. Unlike our study, Guyatt and co-workers failed to define a close association of the six-minute walk test with the results of maximal exercise testing in all patients with heart failure (25). Like our study, however, Cahalin and coworkers concluded that the six-minute walk test was useful in predicting peak $V_{O_2}$ in patients with severe heart failure who were referred for heart transplantation (7). The discrepancy may be explained in part by the difference in the severity of heart failure. The PPH patients in our study had severely limited daily activity (mean NYHA functional class, 3.0 ± 0.6). These results raise the possibility that there is a close association between submaximal exercise and maximal exercise in patients with severely reduced functional capacity. Thus, distance walked during the six-minute walk test may be related to exercise capacity determined by maximal exercise testing in patients with PPH.

In the present study, distance walked in 6 min was negatively correlated with $V_{E}/V_{CO_2}$ slope in patients with PPH. This steeper slope is considered to be associated with increased physiologic dead space resulting from an impaired increase in pulmonary perfusion during exercise (5, 26). Thus, the six-minute walk test may also reflect pulmonary circulation reserve during exercise.

### Six-minute Walk Test and Mortality in PPH

Previous studies have shown that mortality in PPH correlates with RV hemodynamic variables obtained invasively, such as mean pulmonary arterial pressure, cardiac output, and mean right atrial pressure (27, 28). However, a simple, noninvasive, and repeatedly available assessment of the mortality would be more desirable. Interestingly, distance walked during the six-minute walk test has been shown to have a strong, independent association with short-term mortality in patients with severe left-sided heart failure (7, 8). However, whether the six-minute walk test can predict mortality in PPH remains unknown. Earlier studies have shown that pericardial effusion determined by echocardiography is associated with severe pulmonary hypertension and high right atrial pressure, and therefore may serve as a prognostic indicator (11). Sym pathetic nervous system activation, indicated by a high plasma norepinephrine level, has recently been shown to be associated with mortality in patients with PPH (12). Thus, in the present study, these parameters were included in multivariate Cox proportional hazards regression analysis. Among these noninvasive variables, however, only the distance walked in 6 min was the best predictor of mortality. It is interesting to speculate that a decreased cardiac reserve during exercise indicated by a short distance walked in 6 min may be associated with poor outcome in patients with PPH. Furthermore, the Kaplan-Meier survival curves according to the median value of distance walked demonstrated that patients walking < 332 m had a significantly lower survival rate than those walking farther (log-rank test, $p < 0.001$).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Risk Ratio Estimate</th>
<th>95% CI</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.024</td>
<td>0.940–1.115</td>
<td>0.5935</td>
</tr>
<tr>
<td>Sex</td>
<td>0.085</td>
<td>0.002–3.598</td>
<td>0.1970</td>
</tr>
<tr>
<td>Heart rate</td>
<td>1.044</td>
<td>0.917–1.189</td>
<td>0.5173</td>
</tr>
<tr>
<td>$SaO_2$</td>
<td>0.979</td>
<td>0.498–1.924</td>
<td>0.9503</td>
</tr>
<tr>
<td>Pericardial effusion</td>
<td>0.367</td>
<td>0.024–5.530</td>
<td>0.4687</td>
</tr>
<tr>
<td>LV deformity index</td>
<td>1.602</td>
<td>0.317–8.100</td>
<td>0.5689</td>
</tr>
<tr>
<td>Plasma NE</td>
<td>1.000</td>
<td>0.998–1.003</td>
<td>0.7467</td>
</tr>
<tr>
<td>Distance walked in 6 min</td>
<td>0.986</td>
<td>0.973–0.999</td>
<td>0.0381</td>
</tr>
</tbody>
</table>

Definition of abbreviations: CI = confidence interval; LV = left ventricular; NE = norepinephrine; $SaO_2$ = arterial oxygen saturation.
Study Limitations

First, patients with the most severe forms of PPH were excluded from the cardiopulmonary exercise study. However, the conclusions drawn from the data would not have been different even if these patients had been included, because they had markedly poor exercise capacity (distance walked in 6 min = 170 ± 168 m).

Second, it appears to be important to show the relation of peak \( \text{VO}_{2} \) to survival. In the present study, however, this kind of analysis was impossible to perform, because the prognosis of patients completing maximal cardiopulmonary exercise testing was so good.

Third, subsequent therapy, which included vasodilators and anticoagulant agents, was not controlled in this study. Nevertheless, 38 patients (88%) received prostacyclin therapy: intravenous prostacyclin or an oral prostacyclin analogue, both of which have beneficial effects on survival in PPH (9, 10, 13–15).

Venous anticoagulant agents, was not controlled in this study. Nevertheless, 38 patients (88%) received prostacyclin therapy: intravenous prostacyclin or an oral prostacyclin analogue, both of which have beneficial effects on survival in PPH (9, 10, 13–15).

Six-minute walk test would be as good a prognostic indicator in untreated medical therapy, and it may be uncertain that the six-minute walk test, a submaximal exercise test, reflects exercise performance of normal subjects and patients with primary pulmonary hypertension. Am. J. Cardiol. 79:1502–1506.


Finally, our results may apply to the only patients receiving medical therapy, and it may be uncertain that the six-minute walk test would be as good a prognostic indicator in untreated patients.

Conclusions

The six-minute walk test, a submaximal exercise test, reflects exercise capacity determined by maximal cardiopulmonary exercise testing in patients with PPH, and it is the distance walked in 6 min that has a strong, independent association with mortality.

References


